Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. - Wikidata - wikimedia - TriplyDB

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q27777367

about

Somatic DNA mutation analysis in targeted therapy of solid tumours The influence of subclonal resistance mutations on targeted cancer therapy Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges The GIST of targeted therapy for malignant melanoma Tumour heterogeneity and the evolution of polyclonal drug resistance CIViC database KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients A G-Rich Sequence within the c-kit Oncogene Promoter Forms a Parallel G-Quadruplex Having Asymmetric G-Tetrad Dynamics Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.Current management and prognostic features for gastrointestinal stromal tumor (GIST)Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations Structure-guided selection of specificity determining positions in the human Kinome COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.Molecular pathology of sarcomas: concepts and clinical implications Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.The quest to overcome resistance to EGFR-targeted therapies in cancer.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Imatinib: a breakthrough of targeted therapy in cancer.Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT Targeted therapy for cancer: the gastrointestinal stromal tumor model.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Molecular basis and management of gastrointestinal stromal tumors NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.

P2860

10dce7ae4477b0aab93f84e404a3431989171885 6a4774a1eccb33a7192b11a1c42baf07bafe853c 81b49c11862305e2da0d43d101851d4c74529a81 8f42b7ded1bf58bb245c471fc3718777676bc7d4 935c51639f02d4da4afc09543a7238d23dae78f9 bf9debf9632e3d91bde95c455ea7a039c9a4e725 ca051667183aa644df087e2664206b68c5686752 e2437a4338dedb01b8efb1973d24360c163225ce f114d62e3ba3f63cd9fa4c394837ad938ba90649

P248

Q26770324-26D85343-D5F3-406D-8144-146904DD3FDE Q26781693-A3475202-D318-4B57-92AC-F3716528093A Q26799387-0071FFB6-F740-49F6-97BC-9F213A9C47BF Q26823978-A81FE378-AE67-4902-8987-862199B36756 Q26827092-1863AC6E-B9D1-453E-832E-885A30FBC3D4 Q26866803-F88D2F12-3F8F-46EC-8A95-D59680CFFBCD Q27612411-C52BCBEB-C576-49AA-BC1C-7A3E2D87A08A Q27653496-C58406B1-8686-44A7-9D4D-AD2A5A3147E9 Q27657150-8E951E0B-FE5D-4CF0-BB51-EF4EDFC2D3A7 Q27851455-DBC97823-FA67-4C98-8304-B8DECBBCC0AE Q27851482-37BF9146-4559-4AF0-97A5-0ABB4C55192E Q27851660-77005B6E-329A-40CD-B820-0A79023F960E Q27851995-AF2A11E0-656D-4553-9D1D-5376D32DEF97 Q28391684-8F2DA8FB-3124-4D75-BDDA-41BD47343D4F Q28534967-FF7A41C6-B9B5-4E91-B13A-DE197E421A74 Q28541374-9222C523-5ED7-4E60-B181-262B9EF04224 Q28602517-8F1FAEE6-5415-45AD-8B69-3391FC44A02B Q28756824-F32079D2-484D-4E11-8C37-453A6267861D Q28828738-48C3D3A6-CF19-4C49-83E9-346EC87C4CF1 Q29615032-6F969625-EFE1-4E9A-8D1A-463E19136EAA Q30245586-18D2B007-0992-44FE-8B63-212794AF9EE0 Q33410655-08A66D7E-B066-42A4-B9DD-D639EC0323A6 Q33412724-346E17EF-63F1-4937-8FB9-C27D52501479 Q33639728-931D5FC3-A66A-4764-8A64-E1A716CDC7B9 Q33644791-835A1180-9E88-42BC-81D3-989CC40D4F0F Q33654894-0E3A7761-A0E6-4A11-9ABA-513231DA0254 Q33688157-11304611-412B-4E21-9BF3-FAEE1B4761D4 Q33710999-1A357308-9287-4C6F-9DDD-8EB5F9778C6C Q33725976-4DEA44A1-0532-4AAF-AB89-C284493A102F Q33726782-A2075601-9706-4044-84BC-28A3E6853353 Q33747261-B12433A8-1EC9-42F0-8573-916706C1993F Q33794917-FD7CE9D5-33D2-4B35-9B8E-BF5F5B82DB0D Q33807742-F9C68E3F-100D-44C0-A321-211A10B6B0ED Q33817421-528EEC8B-3ED1-43AA-82D3-76049007498E Q33840444-FD69042C-CE8A-460A-9092-CCB74518CB18 Q33895608-0420A810-0C93-40AC-A062-FF888915E66B Q33903598-54654849-BA71-4259-BBE6-1CA09FC8D81C Q33921067-705AA88D-2FC2-4EB9-8304-DA8FCC9E4D65 Q33988695-99C308BF-3102-4E13-8332-F4824F7D7D7C Q34031293-BAC207AC-66FA-437A-9E03-9471B9CB6F99

P2860

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

http://www.wikidata.org/entity/Q27777367

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@ast

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@en

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@nl

type

label

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@ast

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@en

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@nl

prefLabel

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@ast

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@en

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

@nl

P1433

Q27777367-1427EB32-FD6E-43FF-9F2A-642535925855

P1476

Q27777367-5826990D-D0B7-4A8E-8458-3A702529F88D

P2093

Q27777367-144DD872-983D-4F95-93C0-C902118C5F63

Q27777367-3444DBF8-9477-44E4-A650-D248AC0CA8CB

Q27777367-4EED0A64-E621-42A1-A93C-E70715C74FA2

Q27777367-8EC7DA70-E42A-48DF-A0F2-9A71ADCF5F21

Q27777367-90453CD3-1409-4ED1-80D6-7E542F1431CC

Q27777367-A2A1ECA5-3DFE-4D77-82A3-FBB208A816AE

Q27777367-B058F6C7-B6CB-4A90-A0FF-3AB1A5356593

Q27777367-C0A9A014-9A1D-4DFE-811B-AD081174E809

Q27777367-C16367AC-24D8-475F-A50F-2C75B4264309

Q27777367-DF4B8855-1961-41F2-8F31-C1AD59C04520

P304

Q27777367-707B6C05-F586-48A0-945E-C6FEE6C5B9E8

P31

Q27777367-F54727F1-3A3F-4848-A276-2C50A778C496

P3181

Q27777367-F5A4C2CF-5D50-4F61-8037-445BC61A7263

P356

Q27777367-E11CFA99-976C-45C5-8053-5566106B8EB2

P407

Q27777367-ADA17861-5254-4DAB-BBCE-0F396D19F993

P433

Q27777367-8F3653A5-E9F2-4C87-8C67-0ED61B705FEA

P478

Q27777367-CD4774F4-E0A1-42CA-B547-3F364D9C02D4

P50

Q27777367-00DE49BA-3802-4F3D-918C-2FE0AA7D7C5C

Q27777367-6140E315-1148-44A4-AEF9-F6E8E0AEAE52

P577

Q27777367-D782AA87-9062-4D8C-B705-AFCDB01999CD

P5875

Q27777367-323F5D53-5C40-4B69-ACFB-130EC31B2675

P698

Q27777367-ADD6CC83-6040-4245-BF6A-F7F3FEBDA433

P3181

P356

JCO.2006.06.2265

P1433

Journal of Clinical Oncology

P1476

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors

@en

P2093

Burton L Eisenberg

http://www.w3.org/2001/XMLSchema#string

Chang-Jie Chen

http://www.w3.org/2001/XMLSchema#string

Charles D Blanke

http://www.w3.org/2001/XMLSchema#string

Christopher D M Fletcher

http://www.w3.org/2001/XMLSchema#string

Christopher L Corless

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Jonathan A Fletcher

http://www.w3.org/2001/XMLSchema#string

Karen McDougall

http://www.w3.org/2001/XMLSchema#string

Katrin Sandau

http://www.w3.org/2001/XMLSchema#string

Margaret von Mehren

http://www.w3.org/2001/XMLSchema#string

P304

4764-4774

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

389379

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2006.06.2265

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Michael C. Heinrich

P577

2006-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6834831

http://www.w3.org/2001/XMLSchema#string

P698

16954519

http://www.w3.org/2001/XMLSchema#string